Nanoparticle therapeutics: Technologies and methods for overcoming cancer

Eur J Pharm Biopharm. 2015 Nov;97(Pt A):140-51. doi: 10.1016/j.ejpb.2015.10.007. Epub 2015 Oct 26.

Abstract

It is anticipated that by 2030 approximately 13 million people will die of cancer. Common cancer therapy often fails due to the development of multidrug resistance (MDR), resulting in high morbidity and poor patient prognosis. Nanotechnology seeks to use drug delivery vehicles of 1-100 nm in diameter, made up of several different materials to deliver anti-cancer drugs selectively to cancer cells and potentially overcome MDR. Several technologies exist for manufacturing and functionalizing nanoparticles. When functionalized appropriately, nanoparticles have been shown to overcome several mechanisms of MDR in vivo and in vitro, reduce drug side effects and represent a promising new area of anti-cancer therapy. This review discusses the fundamental concepts of enhanced permeability and retention (EPR) effect and explores the mechanisms proposed to enhance preferential "retention" in the tumour. The overall objective of this review was to enhance our understanding in the design and development of therapeutic nanoparticles for treatment of cancer.

Keywords: Active targeting; Drug delivery; Functionalization; Multidrug resistance; Nanoparticle; Passive targeting; Targeted delivery.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Drug Delivery Systems
  • Drug Design
  • Drug Resistance, Multiple
  • Drug Resistance, Neoplasm
  • Humans
  • Nanoparticles*
  • Nanotechnology / methods
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Particle Size

Substances

  • Antineoplastic Agents